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Abstract: Despite advances in knowledge and information on the causes of cancers, prevention, the excellence of diag-
nostic systems, and the great achievements of oncology, the incidence of cancer still seems to be on the rise.
The used chemical medications, in turn, have shown numerous side effects and cellular toxicity. That is why re-
searchers have always been looking for anti-cancer drugs without adverse effects on the patient. Hence, herbal
medicines have received special attention. Curcumin (diferuloylmethane) has been used as a spice in many
countries around the world, including Iran, for centuries. Countless properties of this substance, which is ob-
tained from the plant’s root, such as anti-inflammatory, anti-mutagenic, anti-cancer, anti-fungal have been re-
ported. This substance is able to affect cell signaling through multiple biochemical pathways, proliferation,
differentiation, and cell death. The purpose of writing this review was to examine curcumin and its anti-cancer
properties in a general view for its use in practical medicine.
Curcumin, with its epigenetic changes in the level of chromatin, is effective in regulating the expression of major
and regulatory genes and can play a cancer-preventing role in the cell. Also, this substance and its compounds
with inhibition activity of viral protein ACE-2 and Spike glycoprotein of SARS-CoV-2, and regulation of innate
immune response have shown several roles in the fight against diseases.
To better understand the mechanism of action of turmeric metabolites with stimulant or inhibitory properties,
it is necessary to do more research on the particular effects of Curcumin on various diseases, including cancer,
effective dose and how to use it alone or in combination with other drugs.
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1. Introduction
Traditional medicine is the application of a combination of
knowledge and skills in theories, believes, and local experi-
ences, of various nations in providing health prevention, di-
agnosis, and treatment of diseases, be it physical or mental
(1).
Plant-based medicines including herbs, plant substances,
vegetative extracts, and active ingredients of plants are
known as Herbal plants (1).
Well-known traditional medicine systems are Traditional
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Chinese Medicine (TCM) with a history of more than 3000
years (2), Ayurvedic medicine (Indian system of traditional
medicine) , Unani systems, and in developing countries (3)
like in Africa up to 90% of the population, 70% in India, and
40% in China are consumers of traditional medicine for all
healthcare delivered (1). In the United States, throughout
the year 2007, about 38% of adults and 12% of children used
this type of medication (4, 5). It is estimated that the annual
worldwide market for these products approaches US $60 bil-
lion, annually (6).
The study of specific native plants and their usage in tradi-
tional medicine (Ethnobotany) are considerable in both di-
rect application as therapeutic herbs as well as basic materi-
als for medicine industry (7). The origins of 61% of the 877
small-molecule drugs introduced worldwide between 1981
and 2002 are natural products. About 25% of the drugs pre-
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scribed worldwide are derived from plants (8). Also, 177 ap-
proved worldwide drugs for cancer therapy are reported from
which more than 70% are based on natural or artificial prod-
ucts. Moreover, 90% of Eastern Mediterranean, South-East
Asians, and Western Pacific populations are TCM consumers
(figure 1) (9). The purpose of writing this review article is to
investigate the effect of curcumin on chromatin, gene expres-
sion, and cancer prevention.
For writing this review, various databases such as PubMed,
Google scholar, web of science, Scopus, and SID were con-
sidered for searching through keywords like Curcumin, can-
cer, traditional medicine, gene expression, and more. Arti-
cles whose full text was not available were excluded from the
study. 62 articles, mostly from 2015, as well as reports from
the World Health Organization (WHO), from various periods,
were selected based on which had investigated and evaluated
our desired subjects.
1.1. Curcumin and its ingredients
Turmeric is a product of Curcuma longa and belonging to the
ginger family (10). It is derived from rhizomes of the plant
known as “Indian saffron”, dates back nearly 4000 years and
had probably reached China by 700 AD, East Africa by 800
AD, and West Africa by 1200 AD. It is composed of more than
300 active components such as volatile oil which contain
turmerone, one of the main components of the plant root. Its
components can be divided into 2 main classes 1) Curcumi-
noids and 2) non-Curcuminoids (8). Diferuloylmethane, Nat-
ural yellow, Turmeric yellow, Curcuma, Indian saffron, Halad,
Merita Earth, Terra Merita, and Yellow Ginger, are other syn-
onyms of Curcumin (11).
Chemical and physical properties of Curcumin are summa-
rized in Table1. Curcumin is not approved to have thera-
peutic indications and therefore is not considered as a drug,
yet, but rather is known as an herbal and dietary supplement
and is called a PAINS (pan-assay interference compounds) or
IMPS (invalid metabolic panaceas) (12, 13).
Pleiotropic properties and multiple biological activities
of curcumin are known (14) as Anti-inflammatory (15),
Anti-bacterial (16), Antimutagenic, Anti-fungal, Anti-cancer,
Antioxidant, anti-atherosclerotic, Anti-angiogenic, Anti-
epileptic, Antiviral, Hepatoprotective, Wound-healing, and
Antidiabetic (17, 18). So far, 15,062 articles about curcumin
and 5,423 papers about turmeric medical effects are pub-
lished. 226 of the papers are reported as worldwide clin-
ical trials, 103 are completed experimental research, and
430 have remained as conditional investigations (clinicaltri-
als.gov). Also, according to the Iranian Registry of Clinical
Trials (https://www.irct.ir), 173 clinical trials have been reg-
istered in Iran (19).
1.2. Metabolism/ Pharmacokinetics of Curcumin
Curcumin has poor absorption into the gastrointestinal tract.
Oral administration of a single dose of 2g of curcumin in rats
has resulted in a plasma concentration of fewer than 5µg/mL
of the substance (20). Following entry to the gastrointesti-
nal tract, curcumin is quickly metabolized and forms Cur-
cumin glucuronide, Curcumin sulfate, Tetrahydrocurcumin,
Hexahydrocurcumin, and Exahydrocurcuminol (21). Also,
curcumin would sustain sever latter metabolism in the liver
resulting in major metabolites as glucuronides of tetrahy-
drocurcumin and hexahydrocurcumin, with dihydroferulic
acid and traces of ferulic acid, tetrahydrocurcumin, preserve
anti-inflammatory, and antioxidant attributes (22, 23).
Holder et al. (1978) reported some excreted doses of (3)
H-curcumin in the bile of cannulated rats and showed its
major metabolites were glucuronides of tetrahydrocurcumin
and hexahydrocurcumin, while the minor metabolite was
dihydroferulic acid together with traces of ferulic acid (24).
Wahlstrom B., and Blennow G, (1978) showed that when cur-
cumin is given to rats orally at a dose of 1 g / kg, up to 75%
is excreted in the feces, while small amounts of curcumin ap-
pear in the urine. Measurement of blood plasma levels and
biliary excretion showed that curcumin was poorly absorbed
from the gut while negligible amount appeared in urine (25).
Anticancer effects of curcumin have been studied in different
cancers like Gastrointestinal, Genitourinary, Brain, Breast,
Gynecologic, thoracic, Melanoma, Bone, and Hematological
cancer (26, 27).
Main characteristics of curcumin that are involved in its anti-
cancer property are Anti-inflammatory, Anti-oxidative, Anti-
proliferative, Anti-angiogenic, and Apoptosis inducing (28).
Moreover, curcumin modulates different signaling pathways
from which the following are introduced; PI3K/AKT/mTOR
pathway, MAPK signaling pathway, p53 signaling pathway,
Wnt/β-catenin pathway, NF-KB pathway (29, 30) HIF-1 path-
way, Activating protein-1 pathway, Wilms’ tumor 1 path-
way, Nrf2 pathway, EGFR pathway, STAT3 pathway (31), and
Notch 1 pathway (32, 33). Curcumin suppresses growth,
angiogenesis, invasion, and metastasis of cancers through
up/downregulation of multiple molecular targets (34). More
recently, it is shown that curcumin can modulate the targets
that are inhibited by FDA-approved drugs for the treatment
of cancer (35-37).
1.3. Gene expression changes and epigenetic al-
terations
High-throughput studies have revealed that curcumin affects
the expression of divers’ protein-coding genes and microR-
NAs. Ramachandran et al. (2005) studied gene expression
changes in MCF-7(38). Chiang et al. (2015) incubated NCI-
H460 cells (human non-small-cell lung cancer cell line) with
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and without curcumin (2 µM) for 24 h, and compared gene
expression differences between treated and untreated cells
using high-density microarray (39). The outcome demon-
strated that 170 genes were remarkably upregulated, and
577 genes were seriously downregulated in curcumin-treated
cells. The most of DEGs (differentially expressed genes) were
associated with DNA damage, cell cycle, and survival incu-
bated NCI-H460 cells (40).
1.4. Histone deacetylation
Curcumin functions as an HDAC2 activator in heart failure
(41), while it has been reported that the substance down-
regulates HDAC1, 2, 3, 4, 5, 6, 8 and 11 in various cancer cell
lines and mice (42), and inhibits HDAC activity(43).
1.5. Histone acetylation
Curcumin is a specific inhibitor of the p300/CBP family with
no effects on other HATs like PCAF/GCN5 (44). It acts as
CBP/HAT inhibitor, enhances p300 degradation, inhibits hi-
stone hyper acetylation, down-regulates H3 and H4 activa-
tion, acetylates p53(45), suppress GCN5 linked with hypo-
acetylation of histone H3(42), direct inhibition of p300, HAT
activity suppression (46), hypo acetylation of p65 isoform of
NF-kB(47).
1.6. DNA methylation
Methylation of DNA is a type of transmissible change in the
DNA that does not alter coding nucleotide sequence; how-
ever, it can directly suppresses the expression of a gene. It
has been observed that hypo-methylating activity of cur-
cumin depends on the density of methylation owing to selec-
tive demethylation of partially methylated CpG regions other
than fully-methylated genomic areas (42, 48). Covalently
obstruction of the catalytic thiolate of DNA methyl trans-
ferase I, impedes DNMT3B (49), suppresses methyl trans-
ferase M.SssI at an IC50 of 30 nM, and provokes global ge-
nomic DNA hypo-methylation (50, 51). Curcumin exhibits
reactivation of silenced tumor suppressive genes by induc-
ing demethylation of promoters of RARb2 in human cervical
cancer cell lines and p15INK4B in acute myeloid leukemia
(52) (53), leading to a remarkable tumor suppression induced
the reversal of methylation of Nrf2 promoter in prostate can-
cer cells (54).
Hassan et al. (2015) used DNA pyrosequencing and global
DNA methylation analysis and reported that both curcumin
and its structural analog dimethoxycurcumin (DMC) did not
reveal any significant hypo-methylation activity even at very
high concentrations (55). Surprisingly, they considered the
elevated expression of promoter-methylated genes by DMC
without converting DNA methylation (56).
1.7. miRNA expression
miRNAs regulate the gene expression at the level of mRNA
degradation and translation. miRNAs may suppress cancer
or exert oncogenic effects (57). A classification of specific
miRNAs expression levels which is significantly changed by
curcumin administration is reported (57). Curcumin is used
as an adjuvant and showed that it may have synergistic ef-
fects in combination with chemotherapy or radiotherapy in
eliminating tumor cells (table2) (58, 59). Both turmeric and
curcumin are considered to be generally safe and have not
been linked to liver injury in any consistent way (60). Stud-
ies of its use in various clinical conditions have found low
rates of transient and asymptomatic serum enzyme eleva-
tions during therapy but without instances of clinically ap-
parent acute liver injury (61). Indeed, turmeric has been eval-
uated as therapy of acute and chronic liver injury, although
its efficacy and safety in this situation have not been verified
(62).
1.8. Antiviral activity of curcumin
Recent articles report of Curcumin inhibition activity of viral
entry into cells, suppression of viral replication, stimulation
of interferons (IFNs), and inhibition of viral protein expres-
sion (63). Curcumin has an affinity towards ACE-2 and Spike
glycoprotein of SARS-CoV-2 (64).
The results of recent research show that VCG Plus, a cur-
cumin based substance, can act on 88 hub targets which
are closely connected and associated with immune and in-
flammatory responses (65). VCG Plus showed that it has
the potential to regulate innate immune response by act-
ing on NOD-like and Toll-like signaling pathways to pro-
mote interferon’s production, activate and balance T-cells,
and regulates the inflammatory response through inhibiting
PI3K/AKT, NF-KB and MAPK signaling pathways (65).
2. Conclusion
Examination of Curcumin and its compounds, its interven-
tion in various signaling pathways and control of cells ac-
tivities, and thus its effects on the pathogenesis of diseases,
especially cancer, reveals the numerous benefits of this sub-
stance. Therefore, more research on Curcumin, this golden
substance, is recommended in the treatment of diseases in
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Figure 1: A Brief history of traditional medicine and herbal remedies. T&CM: Traditional Chinese medicine. Illustrated by the authors accord-
ing to Newman DJ, Cragg GM. 2012 (8).
Table 1: Chemical and physical properties of Curcumin (66, 67)
Molecular Weight 368.4 g/mol
Physical Description Solid, Orange-yellow crystalline powder
Melting Point 183.0 ◦C
Solubility Insoluble in cold water Very soluble in ethanol, acetic acid
Fluorescence Slightly fluorescent
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Table 2: A number of recent studies on the effectiveness of curcumin in the treatment of cancers (59)
Type of Cancer Treatment Participants Findings
Advanced or metastatic breast
cancer
Curcumin (500 mg/day) and es-
calated until a dose-limiting tox-
icity + docetaxel (100 mg/m2)
for 7 days every 3 weeks
14 patients Improves biological and Clinical
responses
Pancreatic cancer Curcumin (8000 mg/day) + gem-
citabine (1000 mg/m2) weekly
17 patients Time to tumor progression was
1-12 months and overall survival
was 1-24 months
Chronic myeloid leukemia Imatinib (400 mg twice a day
for 6 weeks) Group B [Turmeric
powder (5 g three times/day) +
imatinib (400 mg twice a day)]
for 6 weeks
50 patients The suppressive effect of nitric
oxide levels was noted at Group
B
Pancreatic cancer Curcumin (1000 mg/day) + gem-
citabine (1000 mg/m2 on day
1 and 8) and 60 mg/m2 of S-
1 orally for 14 consecutive days
every 3 weeks
21 patients Median survival time after initi-
ation of curcumin was 161 days
and 1-year survival rate was 19%
Colorectal liver metastases 5 M curcumin + 2 M oxaliplatin
+ 5 M 5-FU
12 patients Curcumin enhanced the
FOLFOX-based chemother-
apy
Pancreatic cancer Curcumin (2000 mg/day) con-
tinuously (4 capsules, each of
500 mg, every day)
44 patients (13 locally advanced
and 31)
Median progression-free sur-
vival and overall survival were
8.4 and 10.2
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